XP Inc. heads into early June with three ugly data points stacking up: a 15% price drawdown over the past month, a miss-driven earnings hangover from Q1, and a fresh analyst target cut from UBS — all in the same week.
The Q1 print, released on May 18, was the catalyst. Fixed-income revenues slumped, profit came in below estimates, and the stock fell 4.6% on the day. Five days later it had given back another 1.4%. That soft reaction has persisted: XP closed at $16.20 on June 2, down nearly 6% on the week. The CFO change announced in May adds another layer of uncertainty for investors trying to gauge management continuity heading into Q2.
The most notable development on the Street this week is a target cut from UBS. Analyst Thiago Batista maintained his Buy rating but lowered his price objective from $28 to $25 on June 3 — a move that still implies significant upside from current levels but signals reduced conviction on the pace of recovery. The broader analyst consensus has been constructive on XP for some time: Goldman Sachs upgraded the name to Buy back in June 2025, Jefferies initiated at Buy in January 2026, and Citi has maintained Buy as well. The mean price target across the Street sits near $121, but that figure looks inconsistent with the current $16.20 price and the granular targets cited above — the most reliable recent anchor is UBS's revised $25, which on its own implies more than 50% upside from here. Valuation has compressed meaningfully: the price-to-earnings multiple has fallen roughly 13% over the past 30 days to 7.1x, and price-to-book has shed 14% over the same period to 1.5x. At those levels, the market is pricing in sustained pressure on margins rather than any near-term recovery.
Positioning in the lending market tells a much calmer story. Short interest has edged up 3.4% over the past week to 4.4% of the free float — a modest build, but far from alarming. More telling is how loose the borrow market remains: availability runs at roughly 1,850%, meaning there are nearly 19 shares available to borrow for every one already shorted. Cost to borrow is negligible at 0.51%, little changed from recent weeks. The short score of 38.9 — on a 0-to-100 scale — sits comfortably in the lower half, consistent with a stock that has some modest short interest but faces no meaningful squeeze dynamics whatsoever. Fitch's decision to affirm XP's 'BB' credit rating with a Stable outlook on May 28 adds another signal that systemic stress is not a concern at this level.
Where the data gets genuinely interesting is in options positioning. Call buying has surged relative to puts — the put/call ratio fell to just 0.075 this week, roughly half its 20-day average of 0.149, and more than one standard deviation below that mean. The 52-week high on the PCR was 1.18, making the current reading among the most call-heavy of the entire year. That was accompanied by news that traders purchased unusually high volumes of call options on June 3. With the stock down 15% in a month and valuation at multi-year lows, options participants appear to be positioning for a mean-reversion bounce rather than betting on further deterioration.
On the ownership side, the most notable recent move is BW Gestao de Investimentos initiating a $6.4 million position, reported June 3. Among existing holders, Capital Research added over 1.3 million shares in the most recent filing period, FMR (Fidelity) added 1.7 million, and Ninety One added 2.4 million — a cluster of incremental buying from institutional names against the backdrop of a falling price. General Atlantic trimmed 2.1 million shares, and the controlling entity XP Control LLC reduced its stake by 1.6 million shares, the latter worth monitoring for signalling effects given the company's Brazilian-listed peer group — BPAC11 and B3SA3 — both fell roughly 4% on the week, suggesting broad sector pressure rather than XP-specific dislocation.
The next scheduled earnings event is August 17. Between now and then, the key variables are whether fixed-income revenue shows any recovery, how the new CFO shapes near-term guidance, and whether the call-heavy options positioning reflects genuine institutional conviction or merely speculative positioning into a technically oversold tape.
See the live data behind this article on ORTEX.
Open XP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
